By Dr Dianne Lauraine Carey

Journal articles

Law H; Mach M; Howe A; Obeid S; Milner B; Carey C; Elfis M; Fsadni B; Ognenovska K; Phan TG; Carey D; Xu Y; Venturi V; Zaunders J; Kelleher AD; Munier CML, 2022, 'Early expansion of CD38+ICOS+ GC Tfh in draining lymph nodes during influenza vaccination immune response', iScience, 25, pp. 103656, http://dx.doi.org/10.1016/j.isci.2021.103656

Davey RT; Fernández-Cruz E; Markowitz N; Pett S; Babiker AG; Wentworth D; Khurana S; Engen N; Gordin F; Jain MK; Kan V; Polizzotto MN; Riska P; Ruxrungtham K; Temesgen Z; Lundgren J; Beigel JH; Lane HC; Neaton JD; Butts J; Denning E; DuChene A; Krum E; Harrison M; Meger S; Peterson R; Quan K; Shaughnessy M; Thompson G; Vock D; Metcalf J; Dewar R; Rehman T; Natarajan V; McConnell R; Flowers E; Smith K; Hoover M; Coyle EM; Munroe D; Aagaard B; Pearson M; Cursley A; Webb H; Hudson F; Russell C; Sy A; Purvis C; Jackson B; Collaco-Moraes Y; Carey D; Robson R; Sánchez A; Finley E; Conwell D; Losso MH; Gambardella L; Abela C; Lopez P; Alonso H; Touloumi G; Gioukari V; Anagnostou O; Avihingsanon A; Pussadee K; Ubolyam S; Omotosho B; Solórzano C; Petersen T; Vysyaraju K; Rizza SA; Whitaker JA; Nahra R; Baxter J; Coburn P; Gardner EM; Scott JA; Faber L; Pastor E; Makohon L; MacArthur RA; Hillman LM; Farrough MJ; Polenakovik HM; Clark LA; Colon RJ; Kunisaki KM; DeConcini M; Johnson SA; Wolfe CR; Mkumba L; Carbonneau JY; Morris A; Fitzpatrick ME; Kessinger CJ; Salata RA; Arters KA; Tasi CM; Panos RJ; Lach LA, 2019, 'Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial', The Lancet Respiratory Medicine, 7, pp. 951 - 963, http://dx.doi.org/10.1016/S2213-2600(19)30253-X

Peterson RL; Vock DM; Babiker A; Powers JH; Hunsberger S; Angus B; Paez A; Neaton JD; group FTINSIGHTFLU-IVIGS; Carey D, 2019, 'Comparison of an ordinal endpoint to time-to-event, longitudinal, and binary endpoints for use in evaluating treatments for severe influenza requiring hospitalization', Contemporary Clinical Trials Communications, 15, pp. 100401, http://dx.doi.org/10.1016/j.conctc.2019.100401

Simonsen L; Higgs E; Taylor RJ; Wentworth D; Cozzi-Lepri A; Pett S; Dwyer DE; Davey R; Lynfield R; Losso M; Morales K; Glesby MJ; Weckx J; Carey D; Lane C; Lundgren J; Emery S, 2018, 'Using clinical research networks to assess severity of an emerging influenza pandemic', Clinical Infectious Diseases, 67, pp. 341 - 349, http://dx.doi.org/10.1093/cid/ciy088

Mwasakifwa GE; Moore C; Carey D; Amin J; Penteado P; Losso M; Lim P-L; Mohapi L; Molina J-M; Gazzard B; Cooper DA; Boyd M, 2018, 'Relationship between untimed plasma lopinavir concentrations and virological outcome on second-line antiretroviral therapy (vol 32, pg 357, 2018)', AIDS, 32, pp. 683 - 683, http://dx.doi.org/10.1097/01.aids.0000530853.88590.a9

Mwasakifwa GE; Moore C; Carey D; Amin J; Penteado P; Losso M; Lim PL; Mohapi L; Molina JM; Gazzard B; Cooper DA; Boyd M, 2018, 'Relationship between untimed plasma lopinavir concentrations and virological outcome on second-line antiretroviral therapy', AIDS, 32, pp. 357 - 361, http://dx.doi.org/10.1097/QAD.0000000000001688

Amara AB; Else LJ; Carey D; Khoo S; Back DJ; Amin J; Emery S; Puls RL, 2017, 'Comparison of dried blood spots versus conventional plasma collection for the characterization of efavirenz pharmacokinetics in a large-scale global clinical trial-the ENCORE1 study', Therapeutic Drug Monitoring, 39, pp. 654 - 658, http://dx.doi.org/10.1097/FTD.0000000000000448

Dickinson L; Amin J; Else L; Boffito M; Egan D; Owen A; Khoo S; Back D; Orrell C; Clarke A; Losso M; Phanuphak P; Carey D; Cooper DA; Emery S; Puls R, 2016, 'Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study', Clinical Pharmacokinetics, 55, pp. 861 - 873, http://dx.doi.org/10.1007/s40262-015-0360-5

Dickinson L; Amin J; Else L; Boffito M; Egan D; Owen A; Khoo S; Back D; Orrell C; Clarke A; Losso M; Phanuphak P; Carey D; Cooper DA; Emery S; Puls R, 2015, 'Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naive HIV-Infected Patients: Results of the ENCORE1 Study', Clinical Pharmacology and Therapeutics, 98, pp. 406 - 416, http://dx.doi.org/10.1002/cpt.156

Amin J; Becker S; Belloso W; Boffito M; Cooper D; Crabtree-Ramirez B; Duncombe C; Foulkes S; Hill A; Jessen H; Kumar S; Lee MP; Nwizu C; Read T; Rooney J; Schaffer K; Shahar E; Winston A; Wolff M; Young B; Abela C; Avihingsanon A; Boyd M; Carey D; Clarke A; Courtney-Vega K; Delfino M; Donaldson A; Emery S; Espinosa N; Johannesen T; Lin E; Losso M; Moricz A; Pett S; Phanupak P; Puls R; Pussadee K; Sutheerasak P; Tomlins L; Ubolyam S; bin Raja Azwa RIS; Bissio E; Calanni L; Chetchotisakd P; Doong N; Elliott J; Gazzard B; Kelly M; Laplume H; del Carmen Luna N; Lupo S; Messina OG; Mohapi L; Moore R; Nolan D; Orrell C; Perez C; Phanuphak P; Rockstroh J; Rowling D; Supparatpinyo K; Smith D; Villanueva JA; Vlahakis E; Kelleher T; Cunningham P; Merlin K; Yeung J; Shaik A; Fsadni B; Carrera A; Lograsso M; Gulick R; Dunn D; Dolan M; Emery S; Kelleher A, 2015, 'Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study', The Lancet Infectious Diseases, 15, pp. 793 - 802, http://dx.doi.org/10.1016/S1473-3099(15)70060-5

Winston A; Amin J; Clarke A; Else L; Amara A; Owen A; Barber T; Jessen H; Avinghsanon A; Chetchotisakd P; Khoo S; Cooper DA; Emery S; Puls R; Puls R; Carey D; Cunningham P; Kelleher A, 2015, 'Cerebrospinal fluid exposure of efavirenz and its major metabolites when dosed at 400 mg and 600 mg once daily: A randomized controlled trial', Clinical Infectious Diseases, 60, pp. 1026 - 1032, http://dx.doi.org/10.1093/cid/ciu976

Amin J; Becker S; Belloso W; Boffito M; Cooper D; Crabtree-Ramirez B; Duncombe C; Emery S; Foulkes S; Hill A; Jessen H; Kumar S; Lee MP; Losso M; Nwizu C; Phanuphak P; Ripin D; Read T; Rooney J; Schaffer K; Shahar E; Winston A; Wolff M; Young B; Abela C; Boyd M; Carey D; Clarke A; Courtney-Vega K; Dazo C; Delfino M; Donaldson A; Espinosa N; Johannesen T; Kaew-On P; Lin E; Moricz A; Taylor J; Phanupak P; Puls RL; Pussadee K; Sutheerasak P; Tomkins L; Ubolyam S; Shah Bin Raja Azwa RI; Bissio E; Calanni L; Casiro A; Chetchotisakd P; Contarelli J; Doong N; Elliott J; Gazzard B; Kelly M; Del Carmen Luna N; Lupo S; Messina OG; Mohapi L; Moore R; Nolan D; Orrell C; Perez C; Pett S; Rockstroh J; Supparatpinyo K; Smith D; Villanueva JA; Vlahakis E; Kelleher T; Cunningham P; Merlin K; Yeung J; Shaik A; Fsadni B; Carrera A; Lograsso M; Gulick R; Crabtree-Ramiraz B; Winston E; Dunn D; Dolan M; Cooper D; Kelleher A, 2014, 'Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): A randomised, double-blind, placebo-controlled, non-inferiority trial', The Lancet, 383, pp. 1474 - 1482, http://dx.doi.org/10.1016/S0140-6736(13)62187-X

Carey D, 2014, 'Efavirenz 400 mg daily remains non-inferior to 600 mg: 96 week data from the double-blind, placebo-controlled ENCORE1 study.', J Int AIDS Soc, 17, pp. 19523, http://dx.doi.org/10.7448/IAS.17.4.19523

Carey D, 2014, 'Efavirenz 400 mg daily remains non‐inferior to 600 mg: 96 week data from the double‐blind, placebo‐controlled ENCORE1 study', Journal of the International AIDS Society, 17, pp. 19523, http://dx.doi.org/10.7448/ias.17.4.19523

Carey DL; Pett SL; Bloch M; Wand H; MacRae K; Beileiter K; Ray J; Boyd MA; Emery S; Cooper DA, 2012, 'A randomized study of pharmacokinetics, efficacy, and safety of 2 raltegravir plus atazanavir strategies in ART-treated adults', JAIDS: Journal of Acquired Immune Deficiency Syndromes, 60, pp. 143 - 149, http://dx.doi.org/10.1097/QAI.0b013e318252f97e

Wand HC; Carey DL; Calmy A; Law MG; Cooper DA; Emery S; Carr AD, 2011, 'Prospective evidence that HIV lipoatrophy and visceral adiposity are partially independent processes', Open Access Journal of Clinical Trials, 3, pp. 1 - 7, http://dx.doi.org/10.2147/OAJCT.S14359

Carey DL; Amin J; Boyd MA; Petoumenos K; Emery S, 2010, 'Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomised controlled trials', Journal of Antimicrobial Chemotherapy, 65, pp. 1878 - 1888

Almany GR; De Arruda MP; Arthofer W; Atallah ZK; Beissinger SR; Berumen ML; Bogdanowicz SM; Brown SD; Bruford MW; Burdine C; Busch JW; Campbell NR; Carey D; Carstens BC; Chu KH; Cubeta MA; Cuda JP; Cui Z; Datnoff LE; DÁvila JA; Davis ES; Davis RM; Diekmann OE; Eizirik E; Fargallo JA; Fernandes F; Fukuda H; Gale LR; Gallagher E; Gao Y; Girard P; Godhe A; GonÇalves EC; Gouveia L; Grajczyk AM; Grose MJ; Gu Z; HalldÉn C; HÄrnstrÖm K; Hemmingsen AH; Holmes G; Huang CH; Huang CC; Hudman SP; Jones GP; Kanetis L; Karunasagar I; Karunasagar I; Keyghobadi N; Klosterman SJ; Klug PE; Koch J; Koopman MM; KÖppler K; Koshimizu E; KrumbÖck S; Kubisiak T; Landis JB; Lasta ML; Lee CY; Li Q; Li SH; Lin RC; Liu M; Liu N; Liu WC; Liu Y; Loiseau A; Luan W; Maruthachalam KK; McCormick HM; Mellick R; Monnahan PJ; Morielle-Versute E; Murray TE; Narum SR; Neufeld K; De Nova PJG; Ojiambo PS; Okamoto N; Othman AS; Overholt WA; Pardini R; Paterson IG; Patty OA; Paxton RJ; Planes S; Porter C; Pratchett MS; PÜttker T; Rasic G; Rasool B; Rey O; Riegler M; Riehl C; Roberts JMK; Roberts PD; Rochel E; Roe KJ; Rossetto M, 2009, 'Permanent genetic resources added to molecular ecology resources database 1 May 2009-31 July 2009', Molecular Ecology Resources, 9, pp. 1460 - 1466, http://dx.doi.org/10.1111/j.1755-0998.2009.02759.x

Read TRH; Carey DL; Mallon PW; Mijch A; Goodall R; Hudson F; Wand HC; Emery S, 2009, 'Efavirenz plasma concentrations did not predict cessation of therapy due to neuropsychiatric symptoms in a large randomized trial', AIDS, 23, pp. 2222 - 2223, http://dx.doi.org/10.1097/QAD.0b013e32832e95f8

Carey DL; Baker D; Petoumenos K; Chuah J; Rogers G; Watson J; Cooper DA; Emery S; Carr AD, 2009, 'Poly-L-lactic acid for HIV-1 facial lipoatrophy: 48-week follow-up', HIV Medicine, 10, pp. 163 - 172

Calmy A; Carey DL; Mallon PW; Wand HC; Law MG; Cooper DA; Carr AD, 2008, 'Early changes in adipokine levels and baseline limb fat may predict HIV lipoatrophy over 2 years following initiation of antiretroviral therapy', HIV Medicine, 9, pp. 101 - 110, http://dx.doi.org/10.1111/j.1468-1293.2007.00527.x

Carey DL; Liew S; Emery S, 2008, 'Restorative interventions for HIV facial lipoatrophy', AIDS Reviews, 10, pp. 116 - 124

Carey DL; Baker D; Rogers G; Petoumenos K; Chuah J; Easey N; Mahon K; Cooper DA; Emery S; Carr AD, 2007, 'A randomized, multicenter, open-label study of poly-l-lactic acid for HIV-1 facial lipoatrophy', JAIDS: Journal of Acquired Immune Deficiency Syndromes, 46, pp. 581 - 589

Bucciardini R; Fragola V; Massella M; Polizzi C; Mirra M; Goodall RL; Carey DL; Hudson FE; Zajdenverg R; Floridia M, 2007, 'Health-related quality of life outcomes in HIV-Infected patients starting different combination regimens in a randomized multinational trial: The INITIO-QoL substudy', AIDS Research and Human Retroviruses, 23, pp. 1215 - 1222

Wand HC; Calmy A; Carey DL; Samaras K; Carr AD; Law MG; Cooper DA; Emery S, 2007, 'Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV-infected adults', AIDS, 21, pp. 2445 - 2453

Calmy A; Carey DL; Mallon PW; Wand HC; Cooper DA; Law MG; Carr AD, 2006, 'Early changes in adiponectin and leptin levels predict changes in limb fat mass over 2 years following initiation of antiretroviral therapy', Antiviral Therapy, 11, pp. L12 - L12

Yeni PG; Cooper DA; Aboulker J; Babiker AG; Carey DL; Darbyshire JH; Floridia M; Girard P; Goodall R; Hooker M; Mijch AM; Meiffredy V; Salzberger B, 2006, 'Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial.', Lancet, 368, pp. 287 - 298

Carey DL; Wand HC; Martin A; Rothwell S; Emery S; Cooper DA; Carr AD, 2005, 'Evaluation of ultrasound for assessing facial lipoatrophy in a randomized, placebo-controlled trial', AIDS, 19, pp. 1325 - 1327

Kovacic JC; Martin A; Carey DL; Wand HC; Mallon PW; Feneley MP; Emery S; Cooper DA; Carr AD, 2005, 'Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophy', Antiviral Therapy, 10, pp. 135 - 143

Dooley MJ; Allen KM; Doecke CJ; Galbraith KJ; Taylor GR; Bright J; Carey DL, 2004, 'A prospective multicentre study of pharmacist initiated changes to drug therapy and patient management in acute care government funded hospitals', British Journal of Clinical Pharmacology, 57, pp. 513 - 521, http://dx.doi.org/10.1046/j.1365-2125.2003.02029.x

Carr AD; Workman C; Carey DL; Rogers GJ; Martin A; Baker DA; Wand HC; Law MG; Samaras K; Emery S; Cooper DA, 2004, 'No effect of rosiglitazone for treatment of HIV-1 lipoatrophy:randomised, double-blind, placebo-controlled trial', Lancet, 363, pp. 429 - 438, http://dx.doi.org/10.1016/S0140-6736(04)15489-5

Carey DL; Workman C; Rogers GJ; Baker DA; Martin A; Wand HC; Emery S; Cooper DA; Carr AD, 2004, 'Rosiglitazone for HIV lipoatrophy: 84 weeks follow-up', Antiviral Therapy, 9, pp. L46 - L46

Carey DL, 2003, 'Once-daily therapies', Journal of Hiv Therapy, 8, pp. 7 - 11

Ray J; Pang E; Carey DL, 2002, 'Simultaneous determination of indinavir, ritonavir and lopinavir (ABT 378) in human plasma by high-performance liquid chromatography', Journal of Chromatography B - Analytical Technologies in the Biomedical and Life Sciences, 775, pp. 225 - 230

Babiker AG; Darbyshire JH; Cooper DA; Hooker MH; Withnall R; Yeni P; Angarano G; Antunes F; Churchill D; Conway B; Flepp M; Lelekis M; Gatell J; Girard PM; Hemmer R; Lundgren J; Mijch A; Mulcahy F; Ristola M; Salzberger B; Sandström E; Staszewski S; Weber J; De Wit S; Aboulker JP; Emery S; Floridia M; Gartland M; Manion D; Popescu M; Schnittman S; Stek M; Verbiest W; Flandre P; Law M; Schade-Brittinger C; Walker S; Bucciardini R; Boukli N; Carey D; Gargalianos P; Mollerup D; Brun-Vezinet F; Loveday C; Seligmann M, 2001, 'An open-label randomized trial to evaluate different therapeutic strategies of combination therapy in HIV-1 infection: Design, rationale, and methods of the initio trial', Controlled Clinical Trials, 22, pp. 160 - 175, http://dx.doi.org/10.1016/S0197-2456(00)00123-9

Carey DL; Cooper DA, 2000, 'Therapeutic drug monitoring for protease inhibitors', HIV and AIDS current trends, pp. 1 - 3

Carey DL; Day RO; Bowden FJ, 1996, 'Common drug interactions in HIV medicine', MEDICAL JOURNAL OF AUSTRALIA, 164, pp. 605 - 606, http://dx.doi.org/10.5694/j.1326-5377.1996.tb122205.x

Carey DL; Day RO; Bowden FJ, 1996, 'Managing HIV. Common drug interactions in HIV medicine.', Med J Aust, 164, pp. 605 - 606, https://www.ncbi.nlm.nih.gov/pubmed/8637465

Carey DL; Day RO; Bowden FJ, 1996, 'Managing HIV, Quick reference:drug interactions. Common drug interactions in HIV medicine', Medical Journal of Australia, 164, pp. 605 - 606

Carey DL; Day RO; Cairns DR; Pearce GA; Wodak AD; Lauchlan RL, 1992, 'An attempt to influence hypnotic and sedative drug use', Medical Journal of Australia, 156, http://dx.doi.org/10.5694/j.1326-5377.1992.tb139841.x

Tett S; Carey D; Lee HS, 1992, 'Drug interactions with fluconazole [10]', Medical Journal of Australia, 156, pp. 365, http://dx.doi.org/10.5694/j.1326-5377.1992.tb139816.x

Tenant-Flowers M; Boyle MJ; Carey D; Marriott DJ; Harkness JL; Penny R; Cooper DA, 1991, 'Sulphadiazine desensitization in patients with AIDS and cerebral toxoplasmosis', AIDS, 5, pp. 311 - 315

Back to profile page